For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & ...

A recent study on psoriatic arthritis care revealed that patients and clinicians agree on key aspects of disease management ...

Sotyktu is approved to treat plaque psoriasis by the US Food and Drug Administration (FDA ... TYK2 inhibitor for people living with psoriatic arthritis and reinforce the established efficacy ...

Bernstein is one of 830,000 Americans living with a chronic, inflammatory disease known as psoriatic arthritis (PsA ... treatment options for PsA include medications such as NSAIDs, steroids ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis ...

LAPIX plans to submit a third IND for LPX-TI641 in the first quarter of 2025 with the dermatology division at the US-FDA.

A drug advertised on television treats psoriasis and psoriatic arthritis. In Milwaukee, once hitting Catastrophic Coverage, a person would pay almost $1,100 a month. No coinsurance next year will ...